Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors arising in the wall of the gastrointestinal tract. They are rare, with an overall incidence of 6.8 cases per million persons in the United States each year.1 However, in patients aged <40 years, there are only 2.6 cases per million persons annually.2 Insertions, deletions, and missense mutations in the KIT and PDGFRA oncogenes cause approximately 85% of GISTs, whereas BRAF V600E missense mutations lead to approximately 1% of cases.3 We and others recently reported that a small subset of GISTs also occur due to kinase fusions (eg, ETV6-NTRK3, FGFR1-TACC1, FGFR1-HOOK3), a previously unappreciated mechanism for GIST tumorigenesis.4–7
GISTs amenable to resection are generally managed surgically, and patients with tumors harboring high-risk features are recommended to receive adjuvant therapy with imatinib, a tyrosine kinase inhibitor that targets the KIT and PDGFRA oncoproteins, but not BRAF, NTRK3, or FGFR1. Risk of recurrence is determined by tumor size, location, mitotic rate, and tumor rupture. Prediction tools, such as the modified NIH method,8 the Armed Forces Institute of Pathology (AFIP; Miettinen criteria),9 and the Memorial Sloan Kettering Cancer Center nomogram,10 stratify risk and predict the likelihood of tumor recurrence after complete resection. If a tumor is considered high risk, adjuvant imatinib is typically recommended based on the ACOSOG Z900111 and SSG XVIII/AIO12 trials, whose cumulative results demonstrated improved relapse-free survival and overall survival (OS) with at least 3 years of adjuvant imatinib. In the era of precision oncology, these recommendations should be provided in conjunction with genomic analyses that may predict imatinib sensitivity or resistance in order to maximize efficacy and minimize toxicity.
This case presentation reminds clinicians that GIST can occur in women of childbearing age and should remain in the differential diagnosis of an adnexal mass. We also review the genomics of GIST, and present a novel tumor mutation to highlight the emerging importance of molecular profiling in dictating personalized cancer treatment, especially during pregnancy.
Dr. Chmielecki has disclosed that she is an employee of AstraZeneca and has equity in Foundation Medicine and AstraZeneca. Dr. Sicklick has disclosed that he receives grant or research support from Foundation Medicine and Novartis Pharmaceuticals, and serves as a consultant for Loxo Oncology. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev 2015;24:298–302.
Fero KE, Coe TM, Fanta PT. Surgical management of adolescents and young adults with gastrointestinal stromal tumors: a US population-based analysis. JAMA Surg 2017;152:443–451.
Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011;11:865–878.
Shi E, Chmielecki J, Tang CM. FGFR1 and NTRK3 actionable alterations in “wild-type” gastrointestinal stromal tumors. J Transl Med 2016;14:339.
Brenca M, Rossi S, Polano M. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol 2016;238:543–549.
Boikos SA, Pappo AS, Killian JK. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016;2:922–928.
Pantaleo MA, Urbini M, Indio V. Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in quadruple WT GIST. Mol Cancer Res 2017;15:553–562.
Joensuu H, Vehtari A, Riihimaki J. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012;13:265–274.
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70–83.
Gold JS, Gonen M, Gutierrez A. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10:1045–1052.
Dematteo RP, Ballman KV, Antonescu CR. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097–1104.
Joensuu H, Eriksson M, Sundby Hall K. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307:1265–1272.
Scherjon S, Lam WF, Gelderblom H, Jansen FW. Gastrointestinal stromal tumor in pregnancy: a case report. Case Rep Med 2009;2009:456402.
Lanzafame S, Minutolo V, Caltabiano R. About a case of GIST occurring during pregnancy with immunohistochemical expression of epidermal growth factor receptor and progesterone receptor. Pathol Res Pract 2006;202:119–123.
Valente PT, Fine BA, Parra C, Schroeder B. Gastric stromal tumor with peritoneal nodules in pregnancy: tumor spread or rare variant of diffuse leiomyomatosis. Gynecol Oncol 1996;63:392–397.
Mahdaoui S, Hissane EM, Oubaid B. Pregnancy and extragastrointestinal stromal tumor: an exceptional association [in French]. J Gynecol Obstet Biol Reprod (Paris) 2012;41:485–488.
Haloob N, Slesser AA, Haloob AR. An elective combined caesarean section and small bowel GIST resection during the third trimester of pregnancy: report of a case. Int J Surg Case Rep 2013;4:121–124.
Varras M, Vlachakos N, Akrivis C. Malignant gastrointestinal stromal tumor presenting with hemoperitoneum in puerperium: report of a case with review of the literature. World J Surg Oncol 2010;8:95.
Igras ET, Fosh BG, Neuhaus SJ. Maternal GIST in twin pregnancy: case report of a rare and complex management challenge. Gynecol Oncol Case Rep 2012;2:133–135.
Wong TH, Chiu WZ, Breedveld GJ. PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. Brain 2014;137(Pt 5):1361–1373.
Falchook GS, Trent JC, Heinrich MC. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 2013;4:310–315.